Smartkem's 1-for-50 Reverse Split Began Trading Friday. Behind it sit a going-concern warning, a $500 million equity line priced at a discount to the day's low, and board authority for a second consolidation.

by Jonas Halvorsen · August 21, 2026

Companies Reporter, The MicroCap Herald

Smartkem, Inc.'s 1-for-50 reverse stock split became effective at 5:00 p.m. Eastern Time on Thursday, August 20, 2026, with the common stock trading on a split-adjusted basis from Friday, August 21, according to the announcement the company issued on August 19. The company said the purpose was singular: "The reverse stock split is intended to increase the per share trading price of Smartkem's common stock to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market." The release named no compliance deadline.

It also disclosed no share counts. On the mechanics the announcement says only that “The reverse stock split will reduce the number of outstanding shares proportionally, while the number of authorized shares of common stock will not change.” The most recent count the desk could confirm from a company filing is 21,202,911 shares of common stock outstanding, stated as of April 1, 2026 in the annual report and as of April 13, 2026 in a later registration statement. That figure predates more than four months of issuance under the facilities described below, so it is a floor on the pre-split count rather than an estimate of it. The desk could not confirm an actual pre-split or an actual post-split share count from any company disclosure, because the company has published neither.

On fractional shares the company was specific: “Fractional shares will not be issued. Shareholders who would be entitled to receive fractional shares will instead be entitled to the rounding up of their fractional share to the nearest whole share.” Derivatives adjust with the stock: the split “will also proportionately adjust the number of shares underlying the company's outstanding equity awards, warrants, and other equity-based securities, as well as the applicable exercise or conversion prices.”

That last clause matters more here than at most issuers, because Smartkem has a great deal of paper outstanding whose terms move with the price. The annual report for the year ended December 31, 2025, filed in April 2026, is blunt about the underlying condition. It states that “Our recurring losses from operations have raised substantial doubt regarding our ability to continue as a going concern,” and that the company expects “our cash and cash equivalents of $0.4 million as of December 31, 2025 to be insufficient to meet our operating expenses and capital expenditure requirements for at least 12 months.” The filing discloses a $13.0 million comprehensive loss for 2025 against $9.9 million in 2024, a $125.1 million accumulated deficit, and no commercial-scale revenue to date. It also says the company will need to raise capital from time to time and expects to finance its working capital requirements through a combination of equity offerings, debt financings, collaborations and strategic alliances.

The company has been doing exactly that, on terms that are expensive in shares. In a March 26, 2026 registered offering it sold 11,365,350 shares at $0.2303 per share for gross proceeds of $2,617,440. Days later, in a transaction disclosed in a March 31 Form 8-K, it closed a larger deal: 11,411.5 shares of Series A Convertible Preferred Stock with a $1,000 stated value, plus warrants over 23,251,960 common shares, for gross proceeds of $9,129,200. The preferred converts at $0.5812 per share, subject to adjustment, and the warrants carry the same exercise price. Every share count and per-share price in this article that predates August 21 is a pre-split figure and is not comparable to any split-adjusted quotation.

Two features of that March financing deserve attention. The warrants carry “full ratchet anti-dilution protection upon the issuance of shares of Common Stock or Common Stock equivalents (other than certain excluded securities) at a price per share below the then-effective exercise price,” so cheaper subsequent issuance resets the strike downward and increases the share count the warrants command. And the gross figure includes the exchange of $3,750,000 of note principal valued at $4,500,000 — 120 per cent of principal, a 20 per cent premium on the exchanged debt.

Alongside it sits the equity line. Smartkem entered a committed equity purchase agreement with Keystone Capital Partners, LLC, effective March 30, 2026, for up to the lesser of $500,000,000 and 19.99 per cent of the company's outstanding shares. The purchase price is “90% of the lesser of (i) the lowest sale price of the Common Stock on the applicable purchase date and (ii) the volume weighted average price,” with the investor's commitment capped at $5,000,000 per VWAP purchase and a 4.99 per cent beneficial ownership cap on issuance. The company issued 10,000 Series A preferred shares as a commitment fee and has agreed to use 25 per cent of the gross proceeds of any sale under the facility to redeem Series A preferred stock.

The scale of that facility was made explicit in an April 17, 2026 registration statement covering the resale of 146,776,707 shares for Keystone. Against 21,202,911 shares outstanding as of April 13, 2026, the filing states the share count would reach 167,979,618 if all registered shares were issued — close to eight times the count then outstanding — and says plainly that “The sale of shares of our common stock pursuant to the Purchase Agreement will have a dilutive impact on our existing stockholders.” The last reported sale price before that filing was $0.3384 on April 16, 2026, a pre-split figure.

Shareholders have already voted for the capacity to go further. The definitive proxy filed May 18, 2026 for a June 23 annual meeting asked holders to raise authorised common stock from 300,000,000 shares to 5,000,000,000, to approve issuances below the Nasdaq minimum price in excess of 19.99 per cent for both the equity line and Series A conversions and warrant exercises, and to grant “discretionary authority to our Board of Directors to effect up to two reverse stock splits.” A Form 8-K filed June 26 reported that every proposal carried, the authorised-share increase by 13,328,336 votes to 1,033,263 and the reverse split authority by 14,104,710 to 244,767. Friday's 1-for-50 need not be the last.

Overlaying this is a pending change of business. On August 3, 2026 Smartkem announced an all-stock merger with Ferrox Critical Minerals valuing Ferrox at $125 million, with no cash consideration. Critically for dilution, the number of Smartkem shares to be issued was not fixed at signing: it is to be set by the volume-weighted average price of Smartkem stock over the 30 trading days immediately preceding closing, reduced by Ferrox's debt to Smartkem under promissory notes. Closing conditions include approval by both companies' shareholders, effectiveness of a Form S-4, Nasdaq approval, the absence of a material adverse change and required governmental approvals, with a March 31, 2027 termination date. Ferrox chairman and chief executive Terrence Duffy, slated to become chief executive of the combined company, said that “With this merger we will now have the ability to source critical minerals for Smartkem as well as provide excess material to the global market, making Smartkem one of the few vertically integrated public electronics companies.”

The risk statement is not complicated. A company that has disclosed substantial doubt about its ability to continue as a going concern, that held $0.4 million of cash at its last audited year-end, and that funds itself through an equity line priced at 90 per cent of the lower of the day's lowest sale price and the VWAP is one whose share count is a function of its share price. Consolidating 1-for-50 raises the quoted price and cuts the count, but the equity line, the ratchet warrants and the convertible preferred all adjust with it, and the Ferrox consideration is set by a VWAP not yet struck. The split itself is a response to a listing standard: the company said it was intended to satisfy the Nasdaq minimum bid price requirement, it disclosed no compliance deadline, and a failure to regain and hold that requirement exposes the stock to delisting from the Nasdaq Capital Market. Board authority for a second split remains outstanding.

Friday, August 21 had not closed when this piece was filed and no split-adjusted closing price exists. What can be checked from here is whether Smartkem discloses its actual pre- and post-split share counts, whether Nasdaq confirms bid-price compliance, and how many shares the Ferrox VWAP ultimately produces. Nothing above is investment advice.